Elite Pharmaceuticals Management
Management criteria checks 3/4
Elite Pharmaceuticals' CEO is Nasrat Hakim, appointed in Aug 2013, has a tenure of 11.25 years. directly owns 20.74% of the company’s shares, worth $147.01M. The average tenure of the management team and the board of directors is 10.7 years and 13.2 years respectively.
Key information
Nasrat Hakim
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11.3yrs |
| CEO ownership | 20.7% |
| Management average tenure | 10.7yrs |
| Board average tenure | 13.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | US$20m |
| Mar 31 2024 | US$1m | n/a | US$20m |
| Dec 31 2023 | n/a | n/a | US$16m |
| Sep 30 2023 | n/a | n/a | US$18m |
| Jun 30 2023 | n/a | n/a | US$4m |
| Mar 31 2023 | US$1m | US$500k | US$4m |
| Dec 31 2022 | n/a | n/a | US$7m |
| Sep 30 2022 | n/a | n/a | US$7m |
| Jun 30 2022 | n/a | n/a | US$7m |
| Mar 31 2022 | US$1m | US$500k | US$9m |
| Dec 31 2021 | n/a | n/a | US$6m |
| Sep 30 2021 | n/a | n/a | US$6m |
| Jun 30 2021 | n/a | n/a | US$6m |
| Mar 31 2021 | US$1m | US$500k | US$5m |
| Dec 31 2020 | n/a | n/a | US$7m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | US$1m | US$500k | -US$2m |
| Dec 31 2019 | n/a | n/a | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | US$1m | US$500k | -US$9m |
| Dec 31 2018 | n/a | n/a | -US$9m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$3m |
| Mar 31 2018 | US$1m | US$500k | -US$4m |
Compensation vs Market: Nasrat's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Nasrat's compensation has increased whilst the company is unprofitable.
CEO
Nasrat Hakim (63 yo)
11.3yrs
Tenure
US$1,078,000
Compensation
Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has pharmaceutical and medical industry experience in Quality Assurance, A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.3yrs | US$1.08m | 20.74% $ 147.0m | |
| Chief Financial Officer | 1.2yrs | US$532.04k | 0.47% $ 3.3m | |
| Executive Vice President of Operations | 11.3yrs | US$652.47k | 0% $ 0 | |
| Vice President of Investor Relations & Corporate Affairs | 11.8yrs | no data | no data | |
| Vice President of Legal | 10.1yrs | US$412.00k | no data | |
| Chief Commercial Officer | 2.2yrs | US$282.20k | no data |
10.7yrs
Average Tenure
60yo
Average Age
Experienced Management: ELTP's management team is seasoned and experienced (10.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.3yrs | US$1.08m | 20.74% $ 147.0m | |
| Independent Director | 15.1yrs | US$30.00k | 0.30% $ 2.1m | |
| Independent Director | 19.6yrs | US$30.00k | 0.30% $ 2.1m | |
| Independent Director | 8.6yrs | US$30.00k | 0.19% $ 1.4m |
13.2yrs
Average Tenure
72yo
Average Age
Experienced Board: ELTP's board of directors are seasoned and experienced ( 13.2 years average tenure).